Joseph W Kim, MD

Assistant Professor of Medicine (Medical Oncology)

Physician Biography

During his time at the NCI, Dr. Joseph Kim was involved in clinical development of novel immunotherapies, such as therapeutic cancer vaccines and immune checkpoint inhibitors, for prostate cancer and other solid tumors. He is also a recipient of several awards, including Young Investigator Award by Conquer Cancer Foundation, American Society of Clinical Oncology (ASCO). His research interests are in early drug development, particularly immunotherapies for genitourinary cancers and others, as well as in development of biomarkers to predict responses to immunotherapy and those to identify aggressive prostate cancers at high risk of recurrence and progression. He is an active member of Society of Immunotherapy of Cancer and ASCO. His clinical interest is in care of patients with prostate cancer at various stages, muscle invasive bladder cancer and those with metastatic disease.

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Prostate and Urologic Cancers Program

Medical Oncology: Early Drug Development Program | Subset Medical Oncology Faculty

Medical Oncology

Yale Medical Group

Board Certifications

  • Hematology (Internal Medicine)

  • Internal Medicine AB of Internal Medicine (2010)

  • Medical Oncology AB of Internal Medicine (2013)

Clinical Trials

Conditions Study Title
Prostate EC1169-01:Phase I study of PSA Targeting Tubulysin Conjugate EC1169 in Patients with recurrent mCRPC
Prostate ARMOR3-SV: Phase 3 trial of Galeterone Compared to Enzalutamide AR-V7 M1 CRPC
Bladder, Other Urinary JVDC 05 (RANGE): Ramucirumab Plus Docetaxel in Participants With Urothelial Cancer
Bladder, Other Urinary ML29725: Expanded access program for atezolizumab in metastatic urothelial cancer
Bladder, Lung, Other Digestive Organ, Other Urinary, Stomach Ramucirumab + Pembro with Gastric or GEJ Adenocarcinoma, NSCLC or Tcell carcinoma of urothelium
Cervix Uteri, Ovary D3610C00001 - Phase I of AZD5363 under Adaptable Dosing Schedules in Solid Tumors
Bladder, Breast - Female, Colon, Lung, Ovary, Soft Tissue PHASE IB STUDY WITH EXPANSION PHASE TO EVALUATE RO5509554 AND MPDL3280A
Lung, Melanoma, skin, Ovary, Soft Tissue Phase 1b Study Evaluating the Safety, Tolerability and Immunogenicity of CMB305 in NYESO1 Patients
Bladder S1011: Standard or Extended Pelvic Lymphadenectomy in Pts to have Surgery for Invasive Bladder Canc
Bladder Novartis BGJ398: A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies
Melanoma, skin Stand Up To Cancer
Kidney S0931: Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Prostate Medivation (PROSPER): Phase 3 Randomized, Double-Blind Study of Enzalutamide for Nonmetastatic CRPC
Bladder, Other Urinary ASG-22CE-13-2: A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE
Prostate SWOG S1216: Phase III RCT for mCRPC pts comparing ADT and TAK700 with ADT and Bicalutamide
Bladder, Brain and Nervous System, Breast - Female, Cervix Uteri, Colon, Esophagus, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Multiple Myeloma, Non-Hodgkin's Lymphoma, Other Female Genital, Other Male Genital, Pancreas, Prostate, Rectum, Soft Tissue, Stomach, Thyroid PCD4989g: Phase I, Open-label MPDL3280A in solid tumors

Edit this profile

Contact Info

Joseph W Kim, MD
Patient Care Location
Yale Cancer CenterYale-New Haven Hospital
20 York Street, Ste north Pavilion 8 & 4

New Haven, CT 06510
View on map...
Mailing Address
25 York Street
PO Box 208028

New Haven, CT 06520-8028